MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05764namaa22004211i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20241117170146.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
241026s2023 |||a|||f |m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.6 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
615.6 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.08.08.M.Sc.2023.Me.F. |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Merhan Taha El-Nadi Taha Badr, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Formulation and evaluation of a model drug in a certain drug delivery systems / |
| Statement of responsibility, etc. |
By Merhan Taha El-Nadi Taha Badr; Under Supervision of Prof. Dr. Mohamed Ahmed El-Nabarawi, Assoc. Prof. Dr. Mahmoud Hassan Teaima, Assoc. Prof. Dr. Rehab Ahmed Abdelmonem |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
صياغة وتقييم نموذج عقار في بعض المستحضرات الصيدلية / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
142 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) -Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 138-142. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly <br/>heritable ailment and considered one of the most common neurodevelopmental <br/>disorders of childhood. Children with (ADHD) usually have difficulty in paying <br/>attention, controlling impulsive behavior and acting without thoroughly <br/>considering expected results. The major parts of the brain showing dysfunction <br/>in (ADHD) are the prefrontal cortex, caudate nucleus, and cerebellum. The <br/>network activity between these regions is achieved by the regulation of the two <br/>neurotransmitters, dopamine (DA), and norepinephrine (NE) acting in <br/>conjunction with each other. <br/> Atomoxetine (ATM), a non-stimulant, selective noradrenergic <br/>reuptake inhibitor, is indicated orally for treating attention-deficit/hyperactivity <br/>disorder (ADHD) in children above 6 years of age and adults. The bioavailability <br/>of (ATM) is 63% in extensive metabolizers and 94% in poor metabolizers. <br/>Intranasal administration of lyophilized nasal inserts of nanosized <br/>atomoxetine solid lipid nanoparticles (ATM-SLNs) can improve bioavailability, <br/>targeting, adherence to drug therapy, and minimize side effects compared to oral <br/>route of drug administration of conventional oral capsules or solutions. Faster <br/>onset of drug action, overcoming the hepatic first pass metabolism, avoidance of <br/>metabolism by gastro-intestinal tract (GIT) and targeted drug delivery to the brain <br/>can be achieved by intranasal administration as there is high vascularity and large <br/>surface area due to (the superior, middle and inferior turbinates) and the olfactory <br/>region. Targeted drug delivery of atomoxetine to the brain can also be achieved <br/>via the olfactory nerve which constitutes the first cranial pair which terminates at <br/>the olfactory bulb, located just above the ethmoid bone and below the frontal lobe. <br/>The olfactory bulb acts as a relay center for the transmission of the impulses from <br/>the olfactory nerve to the olfactory tract and then to the cerebral cortex (olfactory <br/>cortex). |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
مرض نقص الانتباه وفرط الحركة هو احد الأمراض الشائعة من أمراض اضطرابات الجهاز العصبي وهو مرض شديد الوراثة. عادة ما يواجه الاطفال المصابون باضطراب نقص الانتباه وفرط الحركة صعوبة في التركيز والتحكم في السلوك الأندفاعي والتصرف دون التفكير مليا في النتائج المترتبة علي تصرفاتهم. الأجزاء الرئيسية من الدماغ التي تظهر خللا عند فحص أدمغة الاشخاص المصابين هي الفص الجبهي والمخيخ والنواة المذنبة. يتم التواصل بين هذه الأجزاء عن طريق التآزر بين الناقليين العصبيين وهم النورادرينالين والدوبامين وهم نسبتهم تقل عند مرضي نقص الانتباه وفرط الحركة.<br/>عقار الاتوموكستين هو عقار يزيد من انتاج النورادرينالين بالدماغ وهو لا يسبب التعود وهو يستخدم لعلاج مرض نقص الانتباه وفرط الحركة في الأطفال البالغين من العمر أكثر من ست سنوات والبالغين. تبلغ نسبة الاتاحة الحيوية للدواء حوالي 63 بالمائة في الاشخاص الذين لديهم قدرة عالية في انزيمات الايض وتبلغ الاتاحة الحيوية 94 بالمائة في الاشخاص بطيئي الايض.<br/> تهدف الدراسة إلى صناعة وتقييم اقراص صلبة مجففة بالتبريد تتكون من جزيئات الأتوموكسيتين النانوية الدهنية الصلبة لنقل الدواء مباشرة الي الدماغ وتجاوز عملية التمثيل الغذائي الكبدي الاول. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issued also as CD |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmaceutics |
| Source of heading or term |
qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
ADHD |
| -- |
Atomoxetine HCl |
| -- |
Solid Lipid Nanoparticles (SLNs) |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mohamed Ahmed El-Nabarawi |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mahmoud Hassan Teaima |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Rehab Ahmed Abdelmonem |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2023 |
| Supervisory body |
Mohamed Ahmed El-Nabarawi |
| -- |
Mahmoud Hassan Teaima |
| -- |
Rehab Ahmed Abdelmonem |
| Universities |
Cairo University |
| Faculties |
Faculty of pharmacy |
| Department |
Department of Pharmaceutics and Industrial Pharmacy |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Nourhan |
| Reviser Names |
Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |
